8-Substituted isoquinoline derivative and the use thereof
申请人:Kaneko Shunsuke
公开号:US20100261701A1
公开(公告)日:2010-10-14
The present invention relates to a compound represented by the following formula (1):
wherein D
1
, A
1
, D
2
, R
1
, D
3
, and R
2
each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF
申请人:Asahi Kasei Pharma Corporation
公开号:EP2366699A1
公开(公告)日:2011-09-21
The present invention relates to a compound represented by the following formula (1):
wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE
申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP3321256A1
公开(公告)日:2018-05-16
Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I):
wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.
Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I):
wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.
Ortho-selective C–H borylation of aromaticketones has not been extensively explored. Herein, we report the iridium-catalyzed ortho-selective C–H borylation of aromaticketones using in situ-formed imine as the ligand. Good compatibility is observed for various substituted acetophenones and otheraromaticketones, and corresponding products are obtained with medium to excellent yields.